Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 3/20 | 0.46 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.46 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.46 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18496429 | 0.90 | SLC29A1 (0.48) | ADORA1PRMT6SLC29A1P2RY12ADORA3 | |
| SCHEMBL16919749 | 0.89 | P2RY12 (0.49) | PRMT6P2RY12 | |
| SCHEMBL19442813 | 0.89 | P2RY12 (0.49) | PRMT6P2RY12 | |
| SCHEMBL19146307 | 0.89 | ADORA1 (0.44) | ADORA1PRMT6SLC29A1P2RY12 | |
| SCHEMBL16920449 | 0.89 | P2RY12 (0.49) | PRMT6P2RY12 | |
| SCHEMBL18496420 | 0.89 | P2RY12 (0.45) | ADORA1PRMT6SLC29A1P2RY12ADORA3 | |
| SCHEMBL18496467 | 0.87 | SLC29A1 (0.59) | ADORA1SLC29A1ADORA3ADORA2AADORA2B | |
| SCHEMBL31160198 | 0.87 | SLC29A1 (0.59) | ADORA1SLC29A1ADORA3ADORA2AADORA2B | |
| SCHEMBL13057655 | 0.87 | SLC29A1 (0.45) | ADORA1PRMT6SLC29A1P2RY12 | |
| SCHEMBL8619439 | 0.86 | SLC29A1 (0.47) | ADORA1SLC29A1ADORA3ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233882-B1 | FLUORINATED CYCLIC DINUCLEOTIDES FOR CYTOKINE INDUCTION | KAYLA THERAPEUTICS (FR) | 2019-10-30 | — | — | EP | disclosed |